IMU 4.00% 4.8¢ imugene limited

Check-vacc - possible complete response case study!, page-46

  1. 1,391 Posts.
    lightbulb Created with Sketch. 10578
    Looking forward to your receiving abresponse there Davy.

    On a related note, one possibility is that there have been breast cancer patients on the Vaxxinia trial - I'm sure there are far more patients than available Checkvacc trial spots to be filled . Perhaps the more potent Vaxxinia has out-performed the loaded version of Checkvacc and has essentially negated any overall benefit of this particular viral iteration when compared neat cf33(Vaxxinia)
    Last edited by Zior: 14/11/23
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.